by dyadic | Feb 15, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / February 15, 2021 / Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production...
by dyadic | Feb 3, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / February 3, 2021 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
by dyadic | Feb 2, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / February 2, 2021 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
by dyadic | Jan 11, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
by dyadic | Dec 9, 2020 | Press Releases
JUPITER, FL / ACCESSWIRE / December 9, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to...
by dyadic | Nov 12, 2020 | Press Releases
Six new and expanded animal and human health collaborations since Q2 2020 Expanded presence in the Asia Pacific Region Important progress and expanded animal efficacy data in COVID-19 vaccine and antibody programs ZAPI to conduct additional animal studies for...
